Innoviva (INVA) Equity Income (2022 - 2026)
Innoviva (INVA) reported Equity Income of $157.6 million for Q1 2026, up 1263.55% on a YoY basis from $11.6 million in Q1 2025, and up 412.67% quarter-over-quarter from $30.8 million in Q3 2025.
Innoviva (INVA) Equity Income (2022 - 2026) Analysis & Trends
Innoviva has reported Equity Income for 5 years, with the latest figure at $157.6 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Income rose 1263.55% year-over-year to $157.6 million; the trailing twelve-month figure through Mar 2026 stood at $187.9 million (up 432.36% YoY), and the FY2025 full-year result was $141.4 million, up 320.12% from the prior year.
- Equity Income for Q1 2026 stood at $157.6 million, up from $30.8 million in the prior quarter.
- The five-year high for Equity Income was $157.6 million in Q1 2026, with the low at -$60.1 million in Q2 2024.
- Historically, Equity Income has averaged $12.9 million across 5 years, with a median of $10.3 million in 2022.
- Annual changes were most pronounced in 2024 — Equity Income plunged 201.88% — and 2026, when it surged 1263.55%.
- Innoviva's Equity Income stood at $10.3 million in 2022, then soared by 598.97% to $72.0 million in 2023, then plunged by 125.33% to -$18.2 million in 2024, then jumped by 268.67% to $30.8 million in 2025, then surged by 412.67% to $157.6 million in 2026.
- The last three Equity Income figures came in at $157.6 million (Q1 2026), $30.8 million (Q3 2025), and $13.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Innoviva | 1.65 Bn | 1.05 Bn | 75.83 Mn | 157.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 157.65 Mn |
| Sep 30, 2025 | 30.75 Mn |
| Jun 30, 2025 | 13.08 Mn |
| Mar 31, 2025 | -13.55 Mn |
| Sep 30, 2024 | -18.23 Mn |
| Jun 30, 2024 | -60.11 Mn |
| Mar 31, 2024 | 35.34 Mn |
| Sep 30, 2023 | 71.98 Mn |
| Jun 30, 2023 | -19.91 Mn |
| Mar 31, 2023 | 15.82 Mn |
| Sep 30, 2022 | 10.30 Mn |
| Jun 30, 2022 | -42.82 Mn |
| Mar 31, 2022 | -11.95 Mn |